<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Lanadelumab: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Lanadelumab: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Lanadelumab: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="118877" href="/d/html/118877.html" rel="external">see "Lanadelumab: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="118918" href="/d/html/118918.html" rel="external">see "Lanadelumab: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F51843390"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Takhzyro</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52872395"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Takhzyro</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F51807316"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Kallikrein Inhibitor;</li>
<li>
                        Monoclonal Antibody</li></ul></div>
<div class="block doa drugH1Div" id="F51822152"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a39710ed-d7c6-4808-9b5f-163ad50ecca1">Hereditary angioedema, prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hereditary angioedema, prophylaxis:</b>
<b>SUBQ:</b> Initial: 300 mg every 2 weeks; increasing dosing interval to every 4 weeks may be considered in patients well-controlled (eg, attack free) for &gt;6 months.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F51822155"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F51822156"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F51822154"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F51822153"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="118918" href="/d/html/118918.html" rel="external">see "Lanadelumab: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a39710ed-d7c6-4808-9b5f-163ad50ecca1">Hereditary angioedema, prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hereditary angioedema (HAE), prophylaxis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥2 to &lt;6 years: SUBQ: 150 mg every <b>4 weeks</b>.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥6 to &lt;12 years: SUBQ: Initial: 150 mg every 2 weeks; may consider administering every 4 weeks in patients who are well controlled (eg, attack free) for &gt;6 months.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents: SUBQ: Initial: 300 mg every 2 weeks; may consider administering every 4 weeks in patients who are well controlled (eg, attack free) for &gt;6 months.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51821234"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block dohp drugH1Div" id="F51821235"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F51843863"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adolescents and adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection-site reaction (45% to 56%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (33%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Myalgia (11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Upper respiratory tract infection (44%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (2%), increased serum aspartate aminotransferase (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (4% to 10%)</p></div>
<div class="block coi drugH1Div" id="F51807319"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">There are no contraindications listed in the US manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Hypersensitivity to lanadelumab or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F51822143"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Have occurred. In case of a severe hypersensitivity reaction, discontinue therapy and institute appropriate treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Dosage form specific issues:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p></div>
<div class="block prod-avail drugH1Div" id="F57863758"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Takhzyro 150 mg/mL prefilled syringe: FDA approved February 2023; anticipated availability currently unknown. Takhzyro 150 mg/mL prefilled syringes are indicated for use in pediatric patients 2 to &lt;12 years of age.</p></div>
<div class="block foc drugH1Div" id="F51843391"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Subcutaneous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Takhzyro: Lanadelumab-flyo 300 mg/2 mL (2 mL) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Subcutaneous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Takhzyro: Lanadelumab-flyo 150 mg/mL (1 mL); Lanadelumab-flyo 300 mg/2 mL (2 mL) [contains polysorbate 80]</p></div>
<div class="block geq drugH1Div" id="F51843389"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F51949135"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Takhzyro Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg/2 mL (per mL): $15,351.10</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Prefilled Syringe</b> (Takhzyro Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mg/mL (per mL): $15,351.11</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg/2 mL (per mL): $15,351.10</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52872396"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Takhzyro: Lanadelumab-flyo 300 mg/2 mL (2 mL) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Takhzyro: Lanadelumab-flyo 300 mg/2 mL (2 mL) [contains polysorbate 80]</p></div>
<div class="block adm drugH1Div" id="F51822158"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>SUBQ:</b> For SUBQ injection into the abdomen, thigh, or upper arm. Rotate injection sites; injection site should be ≥2 inches (5 cm) away from any scars or navel. Do not inject in an area that is bruised, swollen, or painful.</p>
<p style="text-indent:-2em;margin-left:2em;">Allow vial or prefilled syringe to reach room temperature before injection (15 minutes). Before preparing dose, gently invert vial 3 to 5 times to mix; do not shake. Use an 18-gauge transfer needle to withdraw dose and a 27-gauge, ½-inch needle or other needle suitable for SUBQ injection to administer dose.</p></div>
<div class="block admp drugH1Div" id="F52614686"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> In addition to administration by health care providers, the vial or prefilled syringe may be used for self-administration or administration by a caregiver after training; self-administration is not recommended in children &lt;12 years of age.</p>
<p style="text-indent:-2em;margin-left:2em;">SUBQ: SUBQ administration only; administer SUBQ into the upper arm (health care provider or caregiver administration only), abdomen, or thigh. Rotate injection sites; injection site should be ≥2 inches (5 cm) away from any scars or navel; each new injection site should be at least 1 inch from the site last used. Do not inject in an area that is irritated, red, bruised, or infected. After administration, do not rub injection site.</p>
<p style="text-indent:-2em;margin-left:4em;">Vial: Allow vial to reach room temperature (15 minutes). Gently invert the vial 3 to 5 times to mix; do not shake; no reconstitution or dilution is necessary. Use an 18-gauge transfer needle to withdraw dose and a 27-gauge, <sup>1</sup>/<sub>2</sub>-inch needle or other needle suitable for SUBQ injection to administer dose; in trials, most patients administered their dose over 10 to 60 seconds. Once dose has been removed from vial, it must be administered within 2 hours if at room temperature, or within 8 hours if refrigerated.</p>
<p style="text-indent:-2em;margin-left:4em;">Prefilled syringe: Allow prefilled syringe to reach room temperature prior to injection (15 minutes). Do not remove needle cap until ready to inject; do not heat prefilled pen in microwave or in hot water. Do not shake. Do not try to remove air bubbles.</p></div>
<div class="block use drugH1Div" id="F51807318"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Hereditary angioedema, prophylaxis:</b> Prevention of attacks of hereditary angioedema in adults and pediatric patients ≥2 years of age.</p></div>
<div class="block cyt drugH1Div" id="F51822003"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F51822000"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Efgartigimod Alfa: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rozanolixizumab: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F51822141"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Adverse events were not observed in animal reproduction studies. Human IgG crosses the placenta. Fetal exposure is dependent upon the IgG subclass, maternal serum concentrations, placental integrity, newborn birth weight, and GA, generally increasing as pregnancy progresses. The lowest exposure would be expected during the period of organogenesis and the highest during the third trimester (Clements 2020; Palmeira 2012; Pentsuk 2009).</p>
<p style="text-indent:0em;margin-top:2em;">If prevention of attacks of hereditary angioedema (HAE) is needed during pregnancy, agents other than lanadelumab are recommended. Patients with HAE should be monitored closely during pregnancy and for at least 72 hours after delivery (WAO/EAACI [Maurer 2022]).</p></div>
<div class="block brc drugH1Div" id="F51822142"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if lanadelumab is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Lanadelumab is a humanized monoclonal antibody (IgG<sub>1</sub>). Human IgG is present in breast milk; concentrations are dependent upon IgG subclass and postpartum age (Anderson 2021).</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother. Lactation may increase the frequency of hereditary angioedema (HAE) attacks; patients with HAE should be monitored closely. Current guidelines recommend agents other than lanadelumab for management of HAE during lactation (WAO/EAACI [Maurer 2022]).</p></div>
<div class="block pha drugH1Div" id="F51822147"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Human monoclonal antibody (IgG1/κ-light chain) that binds plasma kallikrein and inhibits its proteolytic activity, controlling excess bradykinin generation in patients with hereditary angioedema.</p></div>
<div class="block phk drugH1Div" id="F51822148"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 14.1 to 16.6 L</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 14.2 to 15 days</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: 4.11 to 5.17 days</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F52903953"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Takhzyro</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Takhzyro</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Takhzyro</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Takhzyro</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Takhzyro</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Takhzyro</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Takhzyro</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Takhzyro</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Takhzyro</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Takhzyro</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Takhzyro</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Takhzyro</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Takhzyro</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Takhzyro</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Takhzyro</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Takhzyro</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Takhzyro</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Takhzyro</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Takhzyro</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Takhzyro</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Takhzyro</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Takhzyro</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Takhzyro</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Takhzyro</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Takhzyro</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Takhzyro</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Takhzyro</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Takhzyro</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Takhzyro</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Takhzyro</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Takhzyro</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Takhzyro</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Takhzyro</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Takhzyro</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Takhzyro</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lanadelumab-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33956488">
<a name="33956488"></a>Anderson PO. Monoclonal antibodies during breastfeeding. <i>Breastfeed Med.</i> 2021;16(8):591-593. doi:10.1089/bfm.2021.0110<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lanadelumab-drug-information/abstract-text/33956488/pubmed" id="33956488" target="_blank">33956488</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. Available at <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lanadelumab-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33013843">
<a name="33013843"></a>Clements T, Rice TF, Vamvakas G,et al. Update on transplacental transfer of IgG subclasses: impact of maternal and fetal factors. <i>Front Immunol.</i> 2020;11:1920. doi:10.3389/fimmu.2020.01920<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lanadelumab-drug-information/abstract-text/33013843/pubmed" id="33013843" target="_blank">33013843</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lanadelumab-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lanadelumab-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35497649">
<a name="35497649"></a>Maurer M, Magerl M, Betschel S, et al. The international WAO/EAACI guideline for the management of hereditary angioedema - the 2021 revision and update.<i> World Allergy Organ J</i>. 2022;15(3):100627. doi:10.1016/j.waojou.2022.100627<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lanadelumab-drug-information/abstract-text/35497649/pubmed" id="35497649" target="_blank">35497649</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22235228">
<a name="22235228"></a>Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. <i>Clin Dev Immunol</i>. 2012;2012:985646.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lanadelumab-drug-information/abstract-text/22235228/pubmed" id="22235228" target="_blank">22235228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19626656">
<a name="19626656"></a>Pentsuk N, van der Laan JW. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. <i>Birth Defects Res B Dev Reprod Toxicol</i>. 2009;86(4):328-344.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lanadelumab-drug-information/abstract-text/19626656/pubmed" id="19626656" target="_blank">19626656</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8960):1312-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lanadelumab-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Takhzyro.1">
<a name="Takhzyro.1"></a>Takhzyro (lanadelumab-flyo) [prescribing information]. Lexington, MA: Takeda Pharmaceuticals USA; February 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Takhzyro.2">
<a name="Takhzyro.2"></a>Takhzyro (lanadelumab) [product monograph]. Toronto, Ontario, Canada: Takeda Canada Inc; March 2021.</div>
</li></ol></div><div id="topicVersionRevision">Topic 118876 Version 80.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
